Platelets modulate CD4⁺ T-cell function in COVID-19 through a PD-L1 dependent mechanism

Area of Science:

• Immunology
• Hematology
• Virology

Background:

• Severe COVID-19 involves systemic inflammation and impaired CD4+ T-cell function.
• The role of platelets in COVID-19-associated CD4+ T-cell dysfunction is not fully understood.

Purpose of the Study:

• To investigate the contribution of platelets to CD4+ T-cell dysfunction in COVID-19 patients.
• To explore the mechanisms by which platelets affect T-cell functionality in COVID-19.

Main Methods:

• Analysis of CD4+ T cell-platelet aggregates in COVID-19 patients.
• Co-culture experiments of CD4+ T cells with platelets from COVID-19 patients and healthy donors (HD).
• Assessment of T-cell activation markers (CD25), cytokine production (TNF-α, IFN-γ), and PD-L1 expression on platelets.

Main Results:

• Increased CD4+ T cell-platelet aggregates observed in COVID-19 patients, correlating inversely with lymphocyte counts.
• Platelets from COVID-19 patients inhibited CD4+ T-cell activation (CD25 upregulation) and TNF-α production.
• COVID-19 platelets showed high PD-L1 expression, inversely correlated with IFN-γ production by CD4+ T cells.
• PD-L1 blockade restored the ability of COVID-19 platelets to stimulate IFN-γ production.

Conclusions:

• Platelets contribute to CD4+ T-cell dysfunction in COVID-19 through mechanisms involving PD-L1.
• Platelet dysfunction in COVID-19 may exacerbate disease progression by impairing T-cell immunity.
• Targeting platelet-mediated immune suppression could be a therapeutic strategy for severe COVID-19.